Stevanato Group S.p.A. (NYSE: STVN) saw its stock price surge 8% in pre-market trading on Thursday following the release of its impressive third-quarter 2025 financial results. The company, a leading provider of drug containment, drug delivery, and diagnostic solutions, reported revenue of €303.2 million, representing a 9% increase compared to the same period last year and surpassing analyst expectations of €290.4 million.

The strong performance was primarily driven by the company's high-value solutions, which accounted for a record 49% of total revenue. Stevanato reported robust demand for its Nexa syringes and EZ-fill vials, contributing to a 47% year-over-year increase in revenue from high-value solutions. The Biopharmaceutical and Diagnostic Solutions (BDS) segment, in particular, saw a 14% revenue growth, benefiting from favorable timing of product shipments worth approximately €10 million.

Stevanato's adjusted earnings per share came in at €0.14, beating the consensus estimate of €0.13. The company maintained its fiscal 2025 guidance, projecting full-year revenue between €1.16 billion and €1.19 billion, and adjusted EBITDA between €288.5 million and €301.8 million. This outlook, combined with the strong quarterly results, has instilled confidence in investors about Stevanato's growth trajectory and its ability to capitalize on the increasing demand for injectable biologics and biosimilars.